Apellis reports 18-month Phase II data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment. GA is an advanced form

Read the full 405 word article

User Sign In